DARATUMUMAB
daratumumab 1.8 g/15 mL injection, 15 mL vial
DARATUMUMAB (12682L)
12682L
Manner of administration:Injection
Restriction
Indication: Relapsed and/or refractory multiple myeloma
Treatment phase: Continuing treatment of second-line drug therapy from week 25 until disease progression
(administered every 4 weeks)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $6,659.77 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Darzalex SC | |||||